drugset

drugset / Trial / NCT05555589

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589 ↗

Phase 3 Recruiting 70 enrolled ReGenTree, LLC

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)

Timeline

Start: 2023-04-11
Primary completion: 2026-04-30
Completion: 2026-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RGN-259	Unknown	0.1 %	Other

Indications